We assisted GlaxoSmithKline (GSK) with defense of the litigation by serving as one of their science counsel, working with the medical literature and experts. We reviewed the pertinent medical literature and retained experts in both cardiology and diabetes to assist in the defense of these cases.
Defense of GlaxoSmithKline in Avandia Litigation
You Also May Be Interested In:
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.
Represented Boston Children’s Hospital with intellectual property, business, and government contracting issues associated with VaccineFinder